Comphya is a Swiss medical device company, spin-off from the Swiss Federal Institute of Technology (EPFL). Its mission is to overcome the major clinical problems of erectile dysfunction (ED) in spinal cord injury and post-prostatectomy patients (non-responders to oral drugs). Our innovation lies on neuroprosthetics principles and will offer a unique and superior treatment for ED. Our goal is to fulfill patient needs through safe and effective medical devices, offering life quality in large parts of the male population in great need.
Location: Switzerland
Employees: 1-10
Total raised: $16.64M
Founded date: 2017
Investors 3
| Date | Name | Website |
| - | Verve Vent... | verve.vc |
| - | Venture Ki... | venturekic... |
| - | VentureLab | venturelab... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 09.07.2025 | Series A | $9.43M | - |
| 25.02.2025 | Series A | $4.85M | - |
| 31.01.2023 | - | $915.42K | - |
| 01.12.2020 | - | $1.45M | - |
Mentions in press and media 33
| Date | Title | Description |
| 28.01.2026 | New studies validate Aesyra and Comphya devices | EPFL spinoff Aesyra has completed the clinical investigation evaluating the efficacy and safety of its flagship product, AesyBite™ Active. The intelligent oral device combines a customized oral appliance with embedded sensors and active bi... |
| 15.10.2025 | Swiss medtechs report clinical progress in heart, brain, and Urological health | Artiria Medical developed a deflectable guidewire that gives physicians better control and an improved way to navigate the complex network of cerebral arteries compared to existing devices. The distal tip can be shaped, in real-time, witho... |
| 07.10.2025 | Dutch men’s health startup Fellos lands €2 million to tackle sensitive issues like ED and PE through telehealth | The Amsterdam-based online clinic Fellos is scaling rapidly: the platform has raised over €2 million in growth capital from strategic investors, including a group of healthcare professionals, Dutch Operator Fund, and Capital Mills. The plat... |
| 14.07.2025 | Comphya Secures CHF 7.5M for Groundbreaking ED Device, Accelerates U.S. Trials | Comphya, a trailblazing Swiss MedTech firm, closed its CHF 7.5 million Series A funding. This capital propels CaverSTIM, their groundbreaking implantable neuromodulator. CaverSTIM restores erectile function, targeting men post-prostatectomy... |
| 09.07.2025 | Additional funding brings Comphya’s series A to CHF 7.5 million | Earlier this year, Comphya secured CHF 4.35 million in the first tranche of the Series A funding round to support clinical trials of its device, CaverSTIM, the first implantable neuromodulator designed to restore erectile function in patie... |
| 09.07.2025 | Comphya closes CHF 7.5M Series A to advance erectile dysfunction therapy | Lausanne-based Medtech startup Comphya, is developing CaverSTIM, the first implantable neuromodulator designed to restore erectile function in patients unresponsive to medication—particularly those recovering from prostate surgery. The newl... |
| 08.07.2025 | Comphya Raises CHF7.5M in Funding | Comphya SA, a Lausanne, Switzerland-based clinical-stage MedTech company advancing an implantable neurostimulation therapy for erectile dysfunction (ED) unresponsive to medication, closed a Series A financing round. Including the conversion... |
| 08.07.2025 | Swiss MedTech company Comphya raises €8 million to tackle erectile dysfunction with new device | Lausanne-based Comphya SA, a clinical-stage MedTech company innovating the first implantable neurostimulation therapy for erectile dysfunction (ED) unresponsive to medication, today announced the closing of an oversubscribed Series A financ... |
| 01.03.2025 | Comphya's Bold Leap: CHF 4.35M Funding to Revolutionize Erectile Dysfunction Treatment | In the world of medical technology, innovation is the lifeblood. Comphya, a rising star in this arena, has just secured CHF 4.35 million in the first tranche of its Series A funding. This infusion of capital is not just numbers on a balance... |
| 25.02.2025 | Comphya secures CHF 4.35M in Series A first tranche to support CaverSTIM clinical trials | Comphya, a leader in medical technology, has raised CHF 4.35 million in the first tranche of its Series A1 funding round. The amount, which combines converted convertible loans and fresh equity, will help strengthen the company's financial ... |
Show more